Pharmacokinetics of Intrarectal Altrenogest in Horses

Comparison of the efficacy of altrenogest versus transdermal progestin patches on estrus synchronization and ovulation in mares

Background and Aim

The adhesive progestin patch was investigated for estrus synchronization in mares because this method is convenient and safe in other species. This study aimed to compare the efficacy of a transdermal progestin patch versus oral altrenogest on estrus synchronization, preovulatory follicle development, and ovulation.

Materials and Methods

Twenty-four broodmares were randomly divided into two groups. In Group 1, mares (n = 12) were fed 0.044 mg/kg altrenogest daily for 14 days. Group 2 (n = 12) mares were treated with adhesive transdermal progestin patches for 14 days. Mares were observed for estrus daily, from day 3 until day 7, after hormone withdrawal. Follicular development was determined by ultrasonography. The preovulatory follicle size and ovulation time after hormone treatments and ovulation rate were determined for both groups. Plasma progesterone levels were measured during the experimental periods and 2 days after hormone termination in both groups.

Results

The results revealed that the transdermal progestin patch efficiently controlled follicular growth and estrus synchronization in mares. The percentage of mares exhibiting estrus was similar in the altrenogest (100.00%) and transdermal patch (91.67%) groups. Ovulation rates were equivalent with either altrenogest or progestin patch protocols (91.67% [11/12] vs. 83.33% [10/12]). In addition, the preovulatory follicle size was similar in mares treated with altrenogest and progestin patches.

Conclusion

This study revealed that the transdermal progestin patch provides effective estrus synchronization and ovulation, similar to altrenogest treatment. However, the transdermal patch was more convenient with a shorter predictable ovulation time after estrus synchronization and should be considered as an alternative method for mares.

Comparative pharmacokinetic study of two kinds of altrenogest oral solutions for sows

This study was to compare the pharmacokinetic characteristics of domestic altrenogest oral solution (DAOS) or imported altrenogest oral solution (IAOS) in healthy sows. A single administration (1 mg/kg body weight) of DAOS or IAOS was performed in sixteen healthy sows according to a two-period crossover design. Plasma concentrations of altrenogest (AT) were measured by high performance liquid chromatography coupled to a tandem mass spectrometer (HPLC-MS/MS) and the concentration-time data of AT was analyzed by WINNONLIN 5.2. It was suggested that the main pharmacokinetic parameters of DAOS and IAOS were as follows: C_max was 227.59 ± 83.35 ng/mL and 152.83 ± 80.34 ng/mL, T_max was 1.16 ± 0.52 h and 1.58 ± 0.85 h, t_1/2 was 3.63 ± 0.72 h and 3.45 ± 0.63 h, MRT was 5.02 ± 0.79 h and 5.21 ± 0.87 h, AUC_0-t was 1050.23 ± 409.80 h·ng/mL and 778.22 ± 397.84 h·ng/mL, and AUC_0-∞ was 1060 h·ng/mL and 786 h·ng/mL, respectively. The relative bioavailability of DAOS was 134.9%. Above results indicated that oral DAOS was better absorbed than IAOS, C_max of DAOS was higher than that of IAOS (p < 0.05). However, there was no significant difference in the main pharmacokinetic parameters between oral DAOS and IAOS (p > 0.05). Our data confirmed that the absorption, fast elimination and bioavailability of DAOS in sows were better than those of IAOS.

Intramolecular [2 + 2] Photocycloaddition of Altrenogest: Confirmation of Product Structure, Theoretical Mechanistic Insight, and Bioactivity Assessment

While studying the environmental fate of potent endocrine-active steroid hormones, we observed the formation of an intramolecular [2 + 2] photocycloaddition product (2) with a novel hexacyclic ring system following the photolysis of altrenogest (1). The structure and absolute configuration were established by X-ray diffraction analysis. Theoretical computations identified a barrierless two-step cyclization mechanism for the formation of 2 upon photoexcitation. 2 exhibited progesterone, estrogen, androgen, and pregnane X receptor activity, albeit generally with reduced potency relative to 1.